Serina Therapeutics Total Assets Growth & History (SER)
Serina Therapeutics's total assets was $7.0M for fiscal 2025.
View full Serina Therapeutics company overviewSerina Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.0M | $227,000 | +3.38% |
| 2024 | 2024-12-31 | $6.7M | −$2.2M | −25.02% |
| 2023 | 2023-12-31 | $9.0M | $5.7M | +176.70% |
| 2022 | 2022-12-31 | $3.2M | $87,000 | +2.76% |
| 2021 | 2021-12-31 | $3.2M | −$771,000 | −19.64% |
| 2020 | 2020-12-31 | $3.9M | −$3.5M | −47.26% |
| 2019 | 2019-12-31 | $7.4M | −$3.2M | −30.26% |
| 2018 | 2018-12-31 | $10.7M | $1.0M | +10.80% |
| 2017 | 2017-12-31 | $9.6M | — | — |
Serina Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $25.8M | $16.9M | +188.71% |
| Q1 2026 | 2026-03-31 | $27.3M | $20.6M | +305.57% |
| Q4 2025 | 2025-12-31 | $7.0M | $227,000 | +3.38% |
| Q3 2025 | 2025-09-30 | $12.4M | $5.0M | +66.95% |
| Q2 2025 | 2025-06-30 | $8.9M | −$1.8M | −16.50% |
| Q1 2025 | 2025-03-31 | $6.7M | −$4.1M | −38.00% |
| Q4 2024 | 2024-12-31 | $6.7M | −$2.2M | −25.02% |
| Q3 2024 | 2024-09-30 | $7.4M | −$4.8M | −39.11% |
| Q2 2024 | 2024-06-30 | $10.7M | −$1.6M | −12.78% |
| Q1 2024 | 2024-03-31 | $10.9M | −$1.7M | −13.37% |
| Q4 2023 | 2023-12-31 | $9.0M | $5.7M | +176.70% |
| Q3 2023 | 2023-09-30 | $12.2M | $10.2M | +508.07% |
| Q2 2023 | 2023-06-30 | $12.3M | $9.7M | +376.04% |
| Q1 2023 | 2023-03-31 | $12.5M | $9.8M | +361.38% |
| Q4 2022 | 2022-12-31 | $3.2M | $87,000 | +2.76% |
| Q3 2022 | 2022-09-30 | $2.0M | −$419,000 | −17.26% |
| Q2 2022 | 2022-06-30 | $2.6M | $38,000 | +1.50% |
| Q1 2022 | 2022-03-31 | $2.7M | −$444,000 | −14.05% |
| Q4 2021 | 2021-12-31 | $3.2M | −$771,000 | −19.64% |
| Q3 2021 | 2021-09-30 | $2.4M | −$1.8M | −42.26% |
| Q2 2021 | 2021-06-30 | $2.5M | −$2.2M | −46.58% |
| Q1 2021 | 2021-03-31 | $3.2M | −$1.9M | −37.94% |
| Q4 2020 | 2020-12-31 | $3.9M | −$3.5M | −47.26% |
| Q3 2020 | 2020-09-30 | $4.2M | −$4.0M | −48.64% |
| Q2 2020 | 2020-06-30 | $4.8M | −$5.5M | −53.62% |
| Q1 2020 | 2020-03-31 | $5.1M | −$7.2M | −58.67% |
| Q4 2019 | 2019-12-31 | $7.4M | −$3.2M | −30.26% |
| Q3 2019 | 2019-09-30 | $8.2M | — | — |
| Q2 2019 | 2019-06-30 | $10.3M | — | — |
| Q1 2019 | 2019-03-31 | $12.3M | — | — |
| Q4 2018 | 2018-12-31 | $10.7M | $1.0M | +10.80% |
| Q4 2017 | 2017-12-31 | $9.6M | — | — |
Serina Therapeutics total assets trends
Over the last five fiscal years, Serina Therapeutics's total assets increased from $3.9M to $7.0M, a change of $3.0M. The latest reported quarter, Q2 2026, shows $25.8M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Serina Therapeutics source filings ↗